Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does UMECLIDINIUM Cause Interstitial lung disease? 46 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 46 reports of Interstitial lung disease have been filed in association with UMECLIDINIUM (Anoro Ellipta). This represents 0.7% of all adverse event reports for UMECLIDINIUM.

46
Reports of Interstitial lung disease with UMECLIDINIUM
0.7%
of all UMECLIDINIUM reports
1
Deaths
28
Hospitalizations

How Dangerous Is Interstitial lung disease From UMECLIDINIUM?

Of the 46 reports, 1 (2.2%) resulted in death, 28 (60.9%) required hospitalization.

Is Interstitial lung disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for UMECLIDINIUM. However, 46 reports have been filed with the FAERS database.

What Other Side Effects Does UMECLIDINIUM Cause?

Dyspnoea (1,817) Asthma (1,433) Wheezing (1,111) Therapeutic product effect incomplete (980) Cough (913) Drug ineffective (734) Loss of personal independence in daily activities (711) Obstructive airways disorder (654) Chronic obstructive pulmonary disease (588) Condition aggravated (580)

What Other Drugs Cause Interstitial lung disease?

METHOTREXATE (3,049) RITUXIMAB (2,458) PEMBROLIZUMAB (2,113) PREDNISONE (1,850) CYCLOPHOSPHAMIDE (1,725) NIVOLUMAB (1,538) AMIODARONE (1,421) DOXORUBICIN (1,352) ETANERCEPT (1,267) ADALIMUMAB (1,250)

Which UMECLIDINIUM Alternatives Have Lower Interstitial lung disease Risk?

UMECLIDINIUM vs UMECLIDINIUM\VILANTEROL TRIFENATATE UMECLIDINIUM vs UMIFENOVIR UMECLIDINIUM vs UNSPECIFIED INGREDIENT UMECLIDINIUM vs UPADACITINIB UMECLIDINIUM vs URAPIDIL

Related Pages

UMECLIDINIUM Full Profile All Interstitial lung disease Reports All Drugs Causing Interstitial lung disease UMECLIDINIUM Demographics